CMS Entry id: 2710 | Channel: News landing page | Template: news/index



16 March 2017

CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen’s evolocumab

Cambridge Cognition today reports its involvement in Amgen's EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.

8 March 2017

Design and rationale of the EBBINGHAUS trial

The Journal Clinical Cardiology has published on the design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo controlled, multicenter study to assess the effect of the human anti-PCSK9 monoclonal antibody evolocumab on cognitive function in patients with clinically evident cardiovascular disease receiving statin background lipid-lowering therapy1.

7 March 2017

Cambridge Cognition launches web-based testing for virtual research

Cambridge Cognition today announces the launch of a new web-based testing product for conducting academic and clinical research studies online.

6 March 2017

Poster presentation at the International Congress on Schizophrenia Research

Senior Scientist, Kiri Granger, PhD will be presenting a poster at the International Congress on Schizophrenia Research (ICOSR) from the 24th to 28th March.

24 February 2017

Takeda and Cognition Kit partner to pilot wearables in patients with Major Depressive Disorder (MDD)

Takeda Pharmaceuticals U.S.A. and Cognition Kit Limited announce a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD).

25 January 2017

CANTAB Mobile awarded FDA clearance

Cambridge Cognition today announces it has received 510(k) clearance from the U.S. Food and Drug Administration ('FDA') to market its CANTAB Mobile product as a medical device in the U.S.

12 January 2017

Autifony Therapeutics Continues Evaluation of AUT00206 for the Treatment of Schizophrenia

Autifony Therapeutics recently presented a poster at the American College of Neuropsychopharmacology following their first human Phase I study in healthy male volunteers to investigate a novel treatment for the positive, negative and cognitive symptoms of schizophrenia. 

Share this